- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
November 11, 2024Tommy Du Honored With 2024 Sheila Sonenshine Associate Pro Bono Award
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
November 6, 2024How Recent Patent Damages Precedent May Increase Reasonable Royalty Awards
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Federal district court cases that are filed pursuant to the Hatch-Waxman Act
Third Quarter
This chart summarizes the case name, presiding judge, drug, and patents-at-issue in all federal district court cases that are filed pursuant to the Hatch-Waxman Act. It also includes the same information for proceedings before the Patent Trial and Appeal Board concerning Orange Book-listed patents.
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Novo Nordisk Inc. v. Mylan Pharms. Inc., 24-0775 (D. Del.) | 1-Jul-24 | Hon. Colm F. Connolly | Ozempic® (semaglutide subcutaneous solution) | 8,129,343 10,335,462 |
| Currax Pharms. LLC v. Taro Pharm. Indus. Ltd., 24-7446 (D.N.J.) | 1-Jul-24 | Hon. Christine P. O’Hearn | Silenor® (doxepin HCl tablets) | 7,915,307 8,513,299 9,107,898 9,486,437 9,572,814 9,861,607 10,238,620 10,653,660 10,653,662 11,110,074 |
| Bristol-Myers Squibb Co. v. Synthon BV, 24-0780 (D. Del.) | 2-Jul-24 | Hon. Gregory B. Williams | Zeposia® (ozanimod capsules) | 11,680,050 |
| Axsome Malta Ltd. v. Aurobindo Pharma USA, Inc., 24-7511 (D.N.J.) | 2-Jul-24 | Hon. Madeline Cox Arleo | Sunosi® (solriamfetol tablets) | 11,969,404 |
| Currax Pharms. LLC v. Taro Pharm. Indus. Ltd., 24-5040 (S.D.N.Y.) | 2-Jul-24 | Hon. Cathy Seibel | Silenor® (doxepin HCl tablets) | 7,915,307 8,513,299 9,107,898 9,486,437 9,572,814 9,861,607 10,238,620 10,653,660 10,653,662 11,110,074 |
| Novo Nordisk Inc. v. Mylan Pharms. Inc., 24-0067 (N.D.W.V.) | 2-Jul-24 | Hon. Thomas S. Kleeh | Ozempic® (semaglutide subcutaneous solution) | 8,129,343 10,335,462 |
| Veloxis Pharms., Inc. v. Alkem Labs. Ltd., 24-0784 (D. Del.) | 3-Jul-24 | Hon. Jennifer L. Hall | Envarsus XR® (tacrolimus extended-release tablets) | 8,685,998 9,549,918 10,166,190 10,864,199 11,110,081 11,123,331 11,419,823 |
| Salix Pharms., Inc. v. Carnegie Pharms., LLC, 24-7531 (D.N.J.) | 3-Jul-24 | Hon. Susan D. Wigenton | Colazal® (balsalazide disodium capsules) | 7,452,872 7,625,884 |
| Jazz Pharms. Research UK Ltd. v. Apotex Inc., 24-7550 (D.N.J.) | 3-Jul-24 | Hon. Michael E. Farbiarz | Epidiolex® (cannabidiol oral solution) | 11,963,937 |
| Otsuka Pharm. Co., Ltd. v. Sun Pharm. Indus. Ltd., 24-0789 (D. Del.) | 5-Jul-24 | Hon. Jennifer L. Hall | Abilify Maintena® (aripiprazole extended-release injectable suspension) | 10,525,057 10,980,803 1,154,553 11,344,547 11,400,087 11,648,347 |
| Radius Health, Inc. v. Orbicular Pharm. Technologies Private Ltd., 24-11770 (D. Mass.) | 10-Jul-24 | Hon. Richard G. Stearns | Tymlos® (abaloparatide injection) | 11,977,067 |
| Pacira Pharms., Inc. v. eVenus Pharms. Labs. Inc., 24-7680 (D.N.J.) | 10-Jul-24 | Hon. Madeline Cox Arleo | Exparel® (bupivacaine liposome injectable suspension) | 11,925,706 |
| Pierre Fabre Medicament SAS v. Rubicon Research Private Ltd., 24-0811 (D. Del.) | 12-Jul-24 | Hon. Jennifer L. Hall | Hemangeol® (propranolol HCl oral solution) | 8,338,489 8,987,262 |
| Vanda Pharms. Inc. v. MSN Pharms. Inc., 24-0815 (D. Del.) | 12-Jul-24 | Hon. Jennifer L. Hall | Hetlioz LQ® (tasimelteon oral suspension) | 10,179,119 11,266,622 11,285,129 11,850,229 10,610,510 10,980,770 11,759,446 |
| Bristol-Myers Squibb Co. v. Apotex, Inc., 24-0818 (D. Del.) | 15-Jul-24 | Hon. Gregory B. Williams | Zeposia® (ozanimod capsules) | 11,680,050 |
| American Regent, Inc. v. Gland Pharma Ltd., 24-7756 (D.N.J.) | 15-Jul-24 | Hon. Brian R. Martinotti | Tralement® (trace zinc, copper, manganese, selenium injection) Multrys® (trace zinc, copper, manganese, selenium injection) | 11,786,548 11,975,022 11,998,565 |
| American Regent, Inc. v. Fresenius Kabi USA, LLC, 24-0824 (D. Del.) | 16-Jul-24 | Hon. Maryellen Noreika | Selenious Acid | 11,998,565 |
| American Regent, Inc. v. Long Grove Pharms., LLC, 24-0825 (D. Del.) | 16-Jul-24 | Hon. Maryellen Noreika | Selenious Acid | 11,998,565 |
| American Regent, Inc. v. Accord Healthcare Inc., 24-7791 (D.N.J.) | 16-Jul-24 | Hon. Brian R. Martinotti | Selenious Acid | 11,998,565 |
| American Regent, Inc. v. Aspiro Pharma Ltd., 24-7794 (D.N.J.) | 16-Jul-24 | Hon. Brian R. Martinotti | Selenious Acid | 11,998,565 |
| American Regent, Inc. v. Cipla USA, Inc., 24-7796 (D.N.J.) | 16-Jul-24 | Hon. Brian R. Martinotti | Selenious Acid | 11,998,565 |
| American Regent, Inc. v. Dr. Reddy’s Labs., Inc., 24-7799 (D.N.J.) | 16-Jul-24 | Hon. Brian R. Martinotti | Selenious Acid | 11,998,565 |
| American Regent, Inc. v. Fresenius Kabi USA, LLC, 24-7801 (D.N.J.) | 16-Jul-24 | Hon. Brian R. Martinotti | Selenious Acid | 11,998,565 |
| American Regent, Inc. v. Gland Pharma Ltd., 24-7802 (D.N.J.) | 16-Jul-24 | Hon. Brian R. Martinotti | Selenious Acid | 11,998,565 |
| American Regent, Inc. v. Hikma Pharms. USA Inc., 24-7803 (D.N.J.) | 16-Jul-24 | Hon. Brian R. Martinotti | Selenious Acid | 11,998,565 |
| American Regent, Inc. v. Long Grove Pharms., LLC, 24-7804 (D.N.J.) | 16-Jul-24 | Hon. Brian R. Martinotti | Selenious Acid | 11,998,565 |
| American Regent, Inc. v. RK Pharma, Inc., 24-7805 (D.N.J.) | 16-Jul-24 | Hon. Brian R. Martinotti | Selenious Acid | 11,998,565 |
| American Regent, Inc. v. Somerset Therapeutics, LLC, 24-7807 (D.N.J.) | 16-Jul-24 | Hon. Brian R. Martinotti | Selenious Acid | 11,998,565 |
| American Regent, Inc. v. Steriscience Pte. Ltd., 24-7809 (D.N.J.) | 16-Jul-24 | Hon. Brian R. Martinotti | Selenious Acid | 11,998,565 |
| American Regent, Inc. v. Sun Pharm. Indus. Ltd., 24-7810 (D.N.J.) | 16-Jul-24 | Hon. Brian R. Martinotti | Selenious Acid | 11,998,565 |
| American Regent, Inc. v. Xiromed, LLC, 24-7811 (D.N.J.) | 16-Jul-24 | Hon. Brian R. Martinotti | Selenious Acid | 11,998,565 |
| American Regent, Inc. v. Zydus Pharms. (USA) Inc., 24-7812 (D.N.J.) | 16-Jul-24 | Hon. Brian R. Martinotti | Selenious Acid | 11,998,565 |
| Impax Labs., LLC v. Dr. Reddy’s Labs., Ltd., 24-7875 (D.N.J.) | 18-Jul-24 | Hon. Stanley R. Chesler | Rytary® (carbidopa / levodopa extended-release capsules) | 8,557,283 9,089,608 9,463,246 9,533,046 9,901,640 |
| Allergan Pharms. Int’l Ltd. v. Macleods Pharms. Ltd., 24-0847 (D. Del.) | 19-Jul-24 | Hon. Maryellen Noreika | Savella® (milnacipran HCl tablets) | 7,994,220 |
| Ferring Pharms. Inc. v. Jiangsu Hansoh Pharm. Group Co., Ltd., 24-7904 (D.N.J.) | 19-Jul-24 | Hon. Evelyn Padin | Firmagon® (degarelix for injection) | 8,841,081 9,877,999 11,766,468 11,826,397 |
| TherapeuticsMD, Inc. v. Sun Pharm. Indus. Ltd., 24-7974 (D.N.J.) | 24-Jul-24 | Hon. Brian R. Martinotti | Imvexxy® (estradiol vaginal inserts) | 9,180,091 9,289,382 10,258,630 10,398,708 10,471,072 10,537,581 10,568,891 10,668,082 10,806,697 10,835,487 10,888,516 11,065,197 11,116,717 11,123,283 11,241,445 11,246,875 11,266,661 11,304,959 11,351,182 11,497,709 |
| Teva Branded Pharm. Products R&D, Inc. v. Armstrong Pharms., Inc., 24-0869 (D. Del.) | 25-Jul-24 | Hon. Maryellen Noreika | ProAir® HFA (albuterol sulfate inhalation aerosol) | 9,463,289 |
| AstraZeneca Pharms. LP v. Natco Pharma Ltd., 24-8162 (D.N.J.) | 31-Jul-24 | Hon. Robert Kirsch | Lynparza® (olaparib tablets) | 12,048,695 |
| AstraZeneca Pharms. LP v. Sandoz Inc., 24-8164 (D.N.J.) | 31-Jul-24 | Hon. Robert Kirsch | Lynparza® (olaparib tablets) | 12,048,695 |
| AstraZeneca Pharms. LP v. Cipla Ltd., 24-8167 (D.N.J.) | 31-Jul-24 | Hon. Robert Kirsch | Lynparza® (olaparib tablets) | 12,048,695 |
| Astellas Pharma Inc. v. Qilu Pharm. (Hainan) Co., Ltd., 24-8217 (D.N.J.) | Aug. 1, 2024 | Hon. Michael A. Shipp | Xtandi® (enzalutamide tablets) | 7,709,517 11,839,689 |
| Viiv Healthcare Co. v. Hetero USA Inc., 24-0907 (D. Del.) | Aug. 2, 2024 | Hon. Mitchell S. Goldberg | Dovato® (dolutegravir / lamivudine tablets) | 9,242,986 11,234,985 |
| Astellas Pharma Inc. v. Qilu Pharm. (Hainan) Co., Ltd., 24-3747 (E.D. Pa.) | Aug. 1, 2024 | Hon. Wendy Beetlestone | Xtandi® (enzalutamide tablets) | 7,709,517 11,839,689 |
| AstraZeneca AB v. Sciegen Pharms., Inc., 24-0923 (D. Del.) | Aug. 8, 2024 | Hon. Richard G. Andrews | Farxiga® (dapagliflozin tablets) | 8,685,934 7,851,502 8,221,786 8,361,972 8,716,251 7,919,598 8,501,698 |
| AbbVie Inc. v. Hetero USA, Inc., 24-0924 (D. Del.) | Aug. 8, 2024 | Hon. Maryellen Noreika | Rinvoq® (upadacitinib tablets) | RE47,221 8,962,629 11,976,077 11,993,605 11,993,606 |
| Axsome Malta Ltd. v. Alkem Labs. Ltd., 24-8365 (D.N.J.) | Aug. 8, 2024 | Hon. Madeline Cox Arleo | Sunosi® (solriamfetol tablets) | 11,969,404 11,986,454 11,986,455 11,998,639 12,005,036 |
| Pfizer Inc. v. SpecGx LLC, 24-0927 (D. Del.) | Aug. 9, 2024 | Hon. Colm F. Connolly | Xeljanz® (tofacitinib tablets) | RE41,783 |
| Astellas Pharma Inc. v. Lupin Ltd., 24-0939 (D. Del.) | Aug. 13, 2024 | Hon. Joseph F. Bataillon | Myrbetriq® (mirabegron extended-release tablets) | 12,059,409 |
| Astellas Pharma Inc. v. Zydus Pharms. (USA) Inc., 24-0940 (D. Del.) | Aug. 13, 2024 | Hon. Joseph F. Bataillon | Myrbetriq® (mirabegron extended-release tablets) | 12,059,409 |
| Harmony Biosciences, LLC v. AET Pharma US, Inc., 24-0941 (D. Del.) | Aug. 13, 2024 | Hon. Jennifer L. Hall | Wakix® (pitolisant HCl tablets) | 8,486,947 8,207,197 |
| American Regent, Inc. v. Cipla USA, Inc., 24-8435 (D.N.J.) | Aug. 13, 2024 | Hon. Brian R. Martinotti | Tralement® (trace elements injection 4*, USP) | 11,786,548 11,975,022 11,998,565 |
| Janssen Products, L.P. v. Ever Valinject GmbH, 24-7319 (N.D. Ill.) | Aug. 15, 2024 | Hon. Sunil R. Harjani | Yondelis® (trabectedin injection) | 8,895,557 7,420,051 |
| Pfizer Inc. v. Ajanta Pharma Ltd., 24-0953 (D. Del.) | Aug. 16, 2024 | Hon. Colm F. Connolly | Xeljanz® XR (tofacitinib citrate extended-release tablets) | RE41,783 |
| Theravance Biopharma R&D IP, LLC v. Eugia Pharma Specialties Ltd., 24-8558 (D.N.J.) | Aug. 19, 2024 | Hon. Karen M. Williams | Yupelri® (revefenacin inhalation solution) | 12,048,692 |
| Axsome Malta Ltd. v. Aurobindo Pharma USA, Inc., 24-8624 (D.N.J.) | Aug. 21, 2024 | Hon. Madeline Cox Arleo | Sunosi® (solriamfetol tablets) | 11,986,454 11,986,455 11,998,639 12,005,036 |
| Ipsen Biopharms., Inc. v. Conjupro Biotherapeutics, Inc., 24-8723 (D.N.J.) | Aug. 23, 2024 | Hon. Renee Marie Bumb | Onivyde® (irinotecan liposome injection) | 12,059,497 |
| Jazz Pharms. Ireland Ltd. v. Teva Pharms., Inc., 24-8785 (D.N.J.) | Aug. 27, 2024 | Hon. Stanley R. Chesler | Xywav® (calcium, magnesium, potassium, and sodium oxybates oral solution) | 11,986,446 |
| Jazz Pharms. Ireland Ltd. v. Lupin Ltd., 24-8786 (D.N.J.) | Aug. 27, 2024 | Hon. Stanley R. Chesler | Xywav® (calcium, magnesium, potassium, and sodium oxybates oral solution) | 11,986,446 |
| Azurity Pharms., Inc. v. Annora Pharma Private Ltd., 24-8809 (D.N.J.) | Aug. 28, 2024 | Susan D. Wigenton | Firvanq® (vancomycin HCl oral solution) | 10,493,028 10,688,046 10,959,946 10,959,947 10,959,948 10,959,949 11,638,692 |
| Takeda Pharms. U.S.A., Inc. v. Colomba Therapeutics, Inc., 24-0988 (D. Del.) | Aug. 29, 2024 | Hon. Richard G. Andrews | Myinfla® (colchicine tablets) Colcrys® (colchicine tablets) | 7,964,648 |
| Intra-Cellular Therapies, Inc. v. Alkem Labs. Ltd., 24-08845 (D.N.J.) | Aug. 29, 2024 | Hon. Michael A. Shipp | Caplyta® (lumateperone capsules) | 11,980,617 12,070,459 |
| Intra-Cellular Therapies, Inc. v. Aurobindo Pharma Ltd., 24-08848 (D.N.J.) | Aug. 29, 2024 | Hon. Michael A. Shipp | Caplyta® (lumateperone capsules) | 11,980,617 12,070,459 |
| Intra-Cellular Therapies, Inc. v. Dr. Reddy’s Labs. Inc., 24-08850 (D.N.J.) | Aug. 29, 2024 | Hon. Michael A. Shipp | Caplyta® (lumateperone capsules) | 11,980,617 12,070,459 |
| Intra-Cellular Therapies, Inc. v. Hetero USA, Inc., 24-08852 (D.N.J.) | Aug. 29, 2024 | Hon. Michael A. Shipp | Caplyta® (lumateperone capsules) | 11,980,617 12,070,459 |
| Intra-Cellular Therapies, Inc. v. MSN Labs. Private Ltd., 24-08854 (D.N.J.) | Aug. 29, 2024 | Hon. Michael A. Shipp | Caplyta® (lumateperone capsules) | 11,980,617 12,070,459 |
| Intra-Cellular Therapies, Inc. v. Sandoz Inc., 24-08855 (D.N.J.) | Aug. 29, 2024 | Hon. Michael A. Shipp | Caplyta® (lumateperone capsules) | 11,980,617 12,070,459 |
| Intra-Cellular Therapies, Inc. v. Zydus Pharms. (USA) Inc., 24-08856 (D.N.J.) | Aug. 29, 2024 | Hon. Michael A. Shipp | Caplyta® (lumateperone capsules) | 11,980,617 12,070,459 |
| Boehringer Ingelheim Pharms. Inc. v. Mylan Pharms. Inc., 24-0082 (N.D.W.V.) | Aug. 30, 2024 | Hon. Thomas S. Kleeh | Tradjenta® (linagliptin tablets) Jentadueto® (linagliptin / metformin tablets) | 11,911,388 |
| Otsuka Pharm. Co., Ltd. v. Apotex Inc., 24-1004 (D. Del.) | Aug. 30, 2024 | Hon. Jennifer L. Hall | Abilify Maintena® (aripiprazole extended-release injectable suspension) | 10,525,057 10,980,803 11,154,553 11,344,547 11,400,087 11,648,347 |
| Novo Nordisk Inc. v. Mylan Pharms. Inc., 24-1013 (D. Del.) | Sept. 5, 2024 | Hon. Colm F. Connolly | Wegovy® (semaglutide injection) | 12,029,779 |
| Novo Nordisk Inc. v. Sun Pharm. Indus. Ltd., 24-1014 (D. Del.) | Sept. 5, 2024 | Hon. Colm F. Connolly | Wegovy® (semaglutide injection) | 12,029,779 |
| American Regent, Inc. v. Eugia Pharma Specialities Ltd., 24-8956 (D.N.J.) | Sept. 5, 2024 | Hon. Brian R. Martinotti | Selenious Acid | 11,998,565 |
| Rayner Surgical Inc. v. Somerset Therapeutics, LLC, 24-9017 (D.N.J.) | Sept. 6, 2024 | Hon. Evelyn Padin | Omidria® (phenylephrine / ketorolac injection) | 9,066,856 9,486,406 9,855,246 |
| Ingenus Pharms., LLC v. Hetero USA, Inc., 24-1025 (D. Del.) | Sept. 11, 2024 | Hon. Jennifer L. Hall | cyclophosphamide injection | 10,993,952 |
| Jazz Pharms. Ireland Ltd. v. Sandoz, Inc., 24-9110 (D.N.J.) | Sept. 11, 2024 | Hon. Robert Kirsch | Zepzelca® (lurbinectedin injection) | 7,763,615 |
| Jazz Pharms. Ireland Ltd. v. RK Pharma, Inc., 24-1028 (D. Del.) | Sept. 12, 2024 | Hon. Gregory B. Williams | Zepzelca® (lurbinectedin injection) | 7,763,615 |
| Aragon Pharms., Inc. v. Zydus Worldwide DMCC, 24-9134 (D.N.J.) | Sept. 12, 2024 | Hon. Stanley R. Chesler | Erleada® (apalutamide tablets) | 11,963,952 |
| Boehringer Ingelheim Pharms., Inc. v. Anobri Pharms. US, LLC, 24-9135 (D.N.J.) | Sept. 12, 2024 | Hon. Claire C. Cecchi | Stiolto® Respimat® (tiotropium bromide / olodaterol HCl inhalation spray) | 7,396,341 9,027,967 7,837,235 8,733,341 |
| Jazz Pharms. Ireland Ltd. v. InvaGen Pharms., Inc., 24-6416 (E.D.N.Y.) | Sept. 12, 2024 | Hon. Joan M. Azrack | Zepzelca® (lurbinectedin injection) | 7,763,615 |
| Novartis Pharms. Corp. v. Natco Pharma Ltd., 24-1033 (D. Del.) | Sept. 13, 2024 | Hon. Jennifer L. Hall | Kisqali® (ribociclib tablets) | 9,193,732 9,868,739 |
| Mallinckrodt Pharms. Ireland Ltd. v. Baxter Healthcare Corp., 24-1034 (D. Del.) | Sept. 13, 2024 | Hon. Gregory B. Williams | Ofirmev® (acetaminophen injection) | 9,399,012 9,610,265 9,987,238 10,383,834 |
| Axsome Malta Ltd. v. Alkem Labs. Ltd., 24-9209 (D.N.J.) | Sept. 16, 2024 | Hon. Madeline Cox Arleo | Sunosi® (solriamfetol tablets) | 11,969,404 11,986,454 11,986,455 11,998,639 12,005,036 12,036,194 12,064,411 |
| Novartis Pharms. Corp. v. Lupin Inc., 24-1045 (D. Del.) | Sept. 18, 2024 | Hon. Richard G. Andrews | Entresto® (sacubitril / valsartan tablets) | 8,101,659 11,096,918 |
| Supernus Pharms., Inc. v. Micro Labs Ltd., 24-9338 (D.N.J.) | Sept. 20, 2024 | Hon. Zahid N. Quraishi | Trokendi XR® (topiramate extended-release capsules) | 8,298,576 8,298,580 8,663,683 8,877,248 8,889,191 8,992,989 9,549,940 9,555,004 9,622,983 10,314,790 |
| Supernus Pharms., Inc. v. Aurobindo Pharma Ltd., 24-9380 (D.N.J.) | Sept. 23, 2024 | Hon. Karen M. Williams | Oxtellar XR® (oxcarbazepine extended-release tablets) | 7,722,898 7,910,131 8,617,600 8,821,930 9,119,791 9,351,975 9,370,525 9,855,278 10,220,042 11,166,960 11,896,599 |
| Endo Operations, Ltd. v. Fresenius Kabi USA, LLC, 24-1065 (D. Del.) | Sept. 24, 2024 | Hon. Maryellen Noreika | Adrenalin® (epinephrine injection) | 9,119,876 9,295,657 10,130,592 |
| Astellas Pharma Inc. v. Lupin Ltd., 24-1068 (D. Del.) | Sept. 24, 2024 | Hon. Joseph F. Bataillon | Myrbetriq® (mirabegron extended-release tablets) | 12,097,189 |
| Astellas Pharma Inc. v. Zydus Pharms. (USA) Inc., 24-1069 (D. Del.) | Sept. 24, 2024 | Hon. Joseph F. Bataillon | Myrbetriq® (mirabegron extended-release tablets) | 12,097,189 |
| Astellas Pharma Inc. v. Haimen Pharma Inc., 24-9403 (D.N.J.) | Sept. 24, 2024 | Hon. Michael A. Shipp | Xtandi® (enzalutamide tablets) | 7,709,517 11,839,689 |
| Hikma Pharms. USA Inc. v. SK Biopharmaceuticals Co., Ltd., IPR2024-01418 (PTAB) | Sept. 24, 2024 | N/A | Sunosi® (solriamfetol HCl tablets) | 11,560,354 |
| Esperion Therapeutics, Inc. v. Aurobindo Pharma Ltd., 24-9457 (D.N.J.) | Sept. 25, 2024 | Hon. Julien Xavier Neals | Nexlizet® (bempedoic acid / ezetimibe tablets)) | 11,760,714 11,613,511 10,912,751 11,744,816 11,926,584 |
| Ultragenyx Pharm. Inc. v. Navinta LLC, 24-9483 (D.N.J.) | Sept. 26, 2024 | Hon. Esther Salas | Dojolvi® (triheptanoin oral liquid) | 8,697,748 |
| Astellas Pharma Inc. v. Ascent Pharms., Inc., 24-1084 (D. Del.) | Sept. 27, 2024 | Hon. Joseph F. Bataillon | Myrbetriq® (mirabegron extended-release tablets) | 12,059,409 11,707,451 12,097,189 |
| Salix Pharms., Inc. v. Zydus Pharms. (USA) Inc., 24-9512 (D.N.J.) | Sept. 27, 2024 | Hon. Edward S. Kiel | Xifaxan® (rifaximin tablets) | 11,779,571 11,564,912 8,193,196 8,518,949 8,741,904 9,271,968 10,703,763 |
| Bristol-Myers Squibb Co. v. Umedica Labs. Pvt. Ltd., 24-1089 (D. Del.) | Sept. 30, 2024 | Hon. Gregory B. Williams | Eliquis® (apixaban tablets) | 9,326,945 |
| Boehringer Ingelheim Pharms. Inc. v. Granules India Ltd., 24-1091 (D. Del.) | Sept. 30, 2024 | Hon. Colm F. Connolly | Jentadueto® (linagliptin / metformin HCl tablets) | 9,155,705 9,415,016 10,022,379 10,973,827 11,911,388 |
| Axsome Therapeutics, Inc. v. Teva Pharms., Inc., 24-9535 (D.N.J.) | Sept. 30, 2024 | Hon. Madeline Cox Arleo | Auvelity® (dextromethorphan hydrobromide / bupropion HCl extended-release tablets) | 11,986,444 12,036,191 12,042,473 |
GENERICally Speaking Hatch Waxman Bulletin
GENERICally Speaking Hatch Waxman Bulletin
READ MORE Related Publications
September 18, 2024
Astellas Pharma, Inc. v. Sandoz Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 9, 2024
Purdue Pharma L.P v. Accord Healthcare Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 4, 2024
Exeltis USA, Inc. v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
August 28, 2024
Teva Branded Pharm. Products R&D, Inc. v. Deva Holding A.S.
GENERICally Speaking Hatch Waxman Bulletin
August 13, 2024
Allergan USA, Inc. v. MSN Labs. Private Ltd.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.